AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player Dragonfly
Bill Haney is building on his rep as one of the most prolific dealmakers in preclinical R&D, adding a new alliance for Dragonfly Therapeutics with AbbVie on cancer drugs as well as autoimmune diseases — a new field for the upstart developer.
As is generally the case with Dragonfly, hard numbers are scarce, but Celgene, Merck and AbbVie have fronted about $200 million in cash so far, says the CEO, with more than $7 billion in milestones. Haney’s other biotech is Skyhawk, a popular player in the field of drugging RNA, which has grabbed $350 million to $400 million in upfront payments and more than $15 billion in milestones from a slate of partners.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.